Skip to main content
. 2016 Apr 22;95(16):e3417. doi: 10.1097/MD.0000000000003417

FIGURE 2.

FIGURE 2

Study flow. The study population consisted of Crohn disease patients with infliximab (IFX) treatment failure due to a pharmacodynamic (PD) problem or a nonimmune pharmacokinetic (PK) problem. In addition, a cohort of patients in remission on IFX was included.